SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR)...
Hence then, the article about dizal to present emerging data on zegfrovy in non small cell lung cancer at wclc 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 )
Also on site :
- Watch Sheryl Crow Surprise Fans With New ‘Cars’ Song ‘Built to Last’ Ahead of Spin-Off Disney Jr. Series
- Iran, the economy and mending fences: Top takeaways from Trump interview with friend-turned-foe Michael Cohen
- 1972 Hit Song, Featured in ‘Guardians of the Galaxy’ and ‘Almost Famous,’ Became One of the ‘Greatest Singles of All Time’